PURPOSE: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. EXPERIMENTAL DESIGN: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. RESULTS: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. CONCLUSIONS: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.
PURPOSE:Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. EXPERIMENTAL DESIGN: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. RESULTS: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. CONCLUSIONS: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.
Authors: M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas Journal: Genes Dev Date: 2000-07-01 Impact factor: 11.361
Authors: D Gareth R Evans; R T Ramsden; A Shenton; C Gokhale; N L Bowers; S M Huson; G Pichert; A Wallace Journal: J Med Genet Date: 2007-02-16 Impact factor: 6.318
Authors: Shanta M Messerli; Shilpa Prabhakar; Yi Tang; Umar Mahmood; Marco Giovannini; Ralph Weissleder; Rodrick Bronson; Robert Martuza; Samuel Rabkin; Xandra O Breakefield Journal: Hum Gene Ther Date: 2006-01 Impact factor: 5.695
Authors: K D Hadfield; W G Newman; N L Bowers; A Wallace; C Bolger; A Colley; E McCann; D Trump; T Prescott; D G R Evans Journal: J Med Genet Date: 2008-02-19 Impact factor: 6.318
Authors: Brian A Neff; R Mark Wiet; John M Lasak; Noel L Cohen; Harold C Pillsbury; Richard T Ramsden; D Bradley Welling Journal: Laryngoscope Date: 2007-06 Impact factor: 3.325
Authors: Michel Kalamarides; Anat O Stemmer-Rachamimov; Masaya Takahashi; Zhi-Yan Han; Fabrice Chareyre; Michiko Niwa-Kawakita; Peter M Black; Rona S Carroll; Marco Giovannini Journal: Brain Pathol Date: 2007-10-09 Impact factor: 6.508
Authors: Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini Journal: Am J Med Genet A Date: 2011-12-02 Impact factor: 2.802
Authors: Susan M Huson; Maria T Acosta; Allan J Belzberg; Andre Bernards; Jonathan Chernoff; Karen Cichowski; D Gareth Evans; Rosalie E Ferner; Marco Giovannini; Bruce R Korf; Robert Listernick; Kathryn N North; Roger J Packer; Luis F Parada; Juha Peltonen; Vijaya Ramesh; Karlyne M Reilly; John W Risner; Elizabeth K Schorry; Meena Upadhyaya; David H Viskochil; Yuan Zhu; Kim Hunter-Schaedle; Filippo G Giancotti Journal: Am J Med Genet A Date: 2010-12-22 Impact factor: 2.802
Authors: Vivek Subbiah; John Slopis; David S Hong; Leena M Ketonen; Jackson Hamilton; Ian E McCutcheon; Razelle Kurzrock Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Melania Ester Mercado-Pimentel; Craig Miller; Daniela N Rolph; Edrick F Villalobos; Allison M Dunn; Prithvi M Mohan; Suzu Igarashi; Xiangdang Liu; Macken Yrun-Duffy; Neal K Patel; Cecilia M Read; Ross H Francis; Adelina Isabella Lane; Swaroop Murugesh; Abraham Jacob Journal: Otol Neurotol Date: 2017-01 Impact factor: 2.311
Authors: Joseph L Kissil; Jaishri O Blakeley; Rosalie E Ferner; Susan M Huson; Michel Kalamarides; Victor-Felix Mautner; Frank McCormick; Helen Morrison; Roger Packer; Vijaya Ramesh; Nancy Ratner; Katherine A Rauen; David A Stevenson; Kim Hunter-Schaedle; Kathryn North Journal: Am J Med Genet A Date: 2010-02 Impact factor: 2.802
Authors: Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen Journal: Neuro Oncol Date: 2012-07-27 Impact factor: 12.300
Authors: Karo Tanaka; Ascia Eskin; Fabrice Chareyre; Walter J Jessen; Jan Manent; Michiko Niwa-Kawakita; Ruihong Chen; Cory H White; Jeremie Vitte; Zahara M Jaffer; Stanley F Nelson; Allan E Rubenstein; Marco Giovannini Journal: Clin Cancer Res Date: 2013-05-28 Impact factor: 12.531